Pivotal trial data for EP0031 in RET +ve advanced NSCLC, to be presented at ASCO 2026 London, May 22, 2026 Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive [...]
Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China London, January 19, 2026 Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd (“Innolake”) to develop a clinical stage first-in-class antibody drug conjugate [...]
Next-generation Selective RET Inhibitor EP0031(A400) accepted for review by regulatory authorities in China Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today that its partner, Kelun Biotech, has had a new drug application (NDA) for the next generation selective RET [...]
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor London, February 11, 2025: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is to develop a next-generation immuno-oncology drug which could [...]
Ellipses Pharma Launches Pioneering Clinical Trial Programme in Middle East London, December 23, 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the first large-scale Phase 1/2 oncology clinical study of its kind in the [...]
Ellipses Pharma publishes the latest data from an ongoing Phase 1/2 clinical trial of EP0042 at ASH 2024 London, UK, 9th December 2024: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from an ongoing Phase 1/2 clinical trial of EP0042, [...]
Vosilasarm (EP0062), an oral Selective Androgen Receptor Modulator (SARM), poster presented at SABCS 2024 Download larger version About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection [...]
EP0042, a Dual FLT3 and Aurora Kinase Inhibitor, poster presented at ASH 2024 About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding [...]
Rewriting Cancer produced for UICC by BBC Storyworks We are proud to have been involved in the Rewriting Cancer series, produced for UICC by BBC StoryWorks in 2024. This series is separated into three parts: Changing the Odds, Changing the Outcome, and Changing the Experience. Aiming to dispel myths, highlight advancements in cancer diagnosis, prevention, [...]
The innovative use of key opinion leaders in oncology research to improve the clinical trials landscape In the summer 2024 issue of International Clinical Trials, Ellipses Pharma’s Head of Global Drug Development Professor Tobi Arkenau discusses our unique approach to using Ellipses’ unique Scientific Affairs Group to overcome challenges in oncological clinical trials. Read the [...]
